Spatial-Temporal Patterns of β-Amyloid Accumulation: A Subtype and Stage Inference Model Analysis.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
26 04 2022
26 04 2022
Historique:
received:
26
05
2021
accepted:
18
01
2022
pubmed:
17
3
2022
medline:
28
4
2022
entrez:
16
3
2022
Statut:
ppublish
Résumé
β-amyloid (Aβ) staging models assume a single spatial-temporal progression of amyloid accumulation. We assessed evidence for Aβ accumulation subtypes by applying the data-driven Subtype and Stage Inference (SuStaIn) model to amyloid-PET data. Amyloid-PET data of 3,010 participants were pooled from 6 cohorts (ALFA+, EMIF-AD, ABIDE, OASIS, and ADNI). Standardized uptake value ratios were calculated for 17 regions. We applied the SuStaIn algorithm to identify consistent subtypes in the pooled dataset based on the cross-validation information criterion and the most probable subtype/stage classification per scan. The effects of demographics and risk factors on subtype assignment were assessed using multinomial logistic regression. Participants were mostly cognitively unimpaired (n = 1890 [62.8%]), had a mean age of 68.72 (SD 9.1) years, 42.1% were Whereas a 1-trajectory model recovers the established pattern of amyloid accumulation, SuStaIn determined that 3 subtypes were optimal, showing distinct associations with Alzheimer disease risk factors. Further analyses to determine clinical utility are warranted.
Sections du résumé
BACKGROUND AND OBJECTIVES
β-amyloid (Aβ) staging models assume a single spatial-temporal progression of amyloid accumulation. We assessed evidence for Aβ accumulation subtypes by applying the data-driven Subtype and Stage Inference (SuStaIn) model to amyloid-PET data.
METHODS
Amyloid-PET data of 3,010 participants were pooled from 6 cohorts (ALFA+, EMIF-AD, ABIDE, OASIS, and ADNI). Standardized uptake value ratios were calculated for 17 regions. We applied the SuStaIn algorithm to identify consistent subtypes in the pooled dataset based on the cross-validation information criterion and the most probable subtype/stage classification per scan. The effects of demographics and risk factors on subtype assignment were assessed using multinomial logistic regression.
RESULTS
Participants were mostly cognitively unimpaired (n = 1890 [62.8%]), had a mean age of 68.72 (SD 9.1) years, 42.1% were
DISCUSSION
Whereas a 1-trajectory model recovers the established pattern of amyloid accumulation, SuStaIn determined that 3 subtypes were optimal, showing distinct associations with Alzheimer disease risk factors. Further analyses to determine clinical utility are warranted.
Identifiants
pubmed: 35292558
pii: WNL.0000000000200148
doi: 10.1212/WNL.0000000000200148
pmc: PMC9071373
doi:
Substances chimiques
Amyloid
0
Amyloid beta-Peptides
0
Apolipoprotein E4
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1692-e1703Commentaires et corrections
Type : CommentIn
Type : ErratumIn
Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
Alzheimers Dement. 2015 Aug;11(8):964-74
pubmed: 25824567
JAMA. 2011 Jan 19;305(3):275-83
pubmed: 21245183
Alzheimers Dement (Amst). 2017 Jan 23;6:143-151
pubmed: 28239639
Lancet Neurol. 2020 Nov;19(11):951-962
pubmed: 33098804
Alzheimers Res Ther. 2018 Aug 4;10(1):75
pubmed: 30075734
Alzheimers Res Ther. 2019 Mar 21;11(1):27
pubmed: 30902090
Neurology. 2020 Sep 15;95(11):e1538-e1553
pubmed: 32675080
Alzheimers Dement. 2018 Oct;14(10):1281-1292
pubmed: 29792874
Brain. 2012 Jul;135(Pt 7):2115-25
pubmed: 22556189
Nat Med. 2021 May;27(5):871-881
pubmed: 33927414
EJNMMI Res. 2019 Mar 27;9(1):32
pubmed: 30919133
Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2169-2182
pubmed: 33615397
Neurology. 2021 Feb 2;96(5):e662-e670
pubmed: 33184233
J Alzheimers Dis. 2018;62(3):1091-1111
pubmed: 29562540
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Alzheimers Dement. 2015 Jan;11(1):1-15.e1-4
pubmed: 25443857
Alzheimers Dement (Amst). 2017 Jul 01;9:25-34
pubmed: 28795133
J Neurol Neurosurg Psychiatry. 2018 Apr;89(4):410-417
pubmed: 29070646
Neuroimage. 2012 Apr 15;60(3):1880-9
pubmed: 22281676
J Nucl Med. 2020 Feb;61(2):166-171
pubmed: 31836683
JAMA Neurol. 2019 Nov 01;76(11):1319-1329
pubmed: 31314895
Neurology. 2017 Nov 14;89(20):2031-2038
pubmed: 29046362
Neuroimage. 2006 Jul 1;31(3):968-80
pubmed: 16530430
Brain. 2014 Sep;137(Pt 9):2564-77
pubmed: 25012224
Nat Commun. 2018 Oct 15;9(1):4273
pubmed: 30323170
J Nucl Med. 2019 Apr;60(4):541-547
pubmed: 30315145
Brain. 2016 May;139(Pt 5):1551-67
pubmed: 26962052
Alzheimers Dement (N Y). 2016 Mar 03;2(2):82-92
pubmed: 29067295
PLoS One. 2013 Nov 06;8(11):e73377
pubmed: 24223109